myelodysplastic syndromes (MDS) | Page 153 | Aplastic Anemia & MDS International Foundation Return to top.

myelodysplastic syndromes (MDS)

Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndromes

Author(s): 
Platzbecker U
Primary Author: 
Platzbecker U
Journal Title: 
Semin Hematol
Original Publication Date: 
Oct 2012

Despite new developments in innovative and potentially targeted drugs like hypomethylating agents (HMA), allogeneic hematopoietic stem cell transplantation (HCT) is still the only potentially curative treatment option for patients with

Bone Marrow Disease(s): 

Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes

Author(s): 
Komrokji RS, Corrales-Yepez M, Kharfan-Dabaja MA, Al Ali NH, Padron E, Rollison DE, Pinilla-Ibarz J, Zhang L, Epling-Burnette PK, Lancet JE, List AF
Primary Author: 
Komrokji RS
Journal Title: 
Am J Hematol
Original Publication Date: 
Aug 2012

We hypothesized that hypoalbuminemia is an independent prognostic factor in patients with

Bone Marrow Disease(s): 

Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies

Author(s): 
Damaj G, Duhamel A, Robin M, Beguin Y, Michallet M, Mohty M, Vigouroux S, Bories P, Garnier A, El Cheikh J, Bulabois CE, Huynh A, Bay JO, Legrand F, Deconinck E, Fegueux N, Clement L, Dauriac C, Maillard N, Cornillon J, Ades L, Guillerm G, Schmidt-Tanguy
Primary Author: 
Damaj G
Journal Title: 
J Clin Oncol
Original Publication Date: 
Oct 2012

PURPOSETo investigate the impact of prior-to-transplantation

Bone Marrow Disease(s): 

Caregivers

Over 65 million Americans take care of other adults, often parents or spouses, or children with special medical needs. Caregivers may be a day-to-day lifeline for patients, or they may support them from afar in otherways. These generous people need support to understand how they can best play their role. 

B. Douglas Smith, MD

Smith, B. Douglas
Professor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University

B. Douglas Smith is Professor of Oncology at Johns Hopkins University School of Medicine in Baltimore, Maryland, and is on the active staff of Johns Hopkins Hospital. He earned his medical degree at the Medical College of Pennsylvania in Philadelphia, after which he completed an internship, residency, and chief residency at Strong Memorial Hospital in Rochester, New York.  At the completion of his fellowship in Oncology at Johns Hopkins University, he joined the faculty in the Division of Hematologic Malignancies. 

Historical perspectives on myelodysplastic syndromes

Author(s): 
Steensma DP
Primary Author: 
Steensma DP
Journal Title: 
Leuk Res
Original Publication Date: 
Aug 2012

Although Georg Hegel quipped, "We learn from history that we do not learn from history", Aldous Huxley expressed a more nuanced view: "The charm of history and its enigmatic lesson consist in the fact that, from age to age, nothing changes and yet everything is completely different." In order to understand present-day positions and peculiarities in any field of human endeavor, familiarity with the past is essential.

Bone Marrow Disease(s): 

Serial assessment of suspected myelodysplastic syndromes: significance of flow cytometric findings validated by cytomorphology, cytogenetics, and molecular genetics

Author(s): 
Kern W, Haferlach C, Schnittger S, Alpermann T, Haferlach T
Primary Author: 
Kern W
Journal Title: 
Haematologica
Original Publication Date: 
Aug 2012

Background. The significance of

Bone Marrow Disease(s): 
Share with addtoany.com.